In preclinical studies, JAK1/2 inhibitors were shown to alleviate the autoreactive T cell burden and inflammation of T1D (24), and, in clinical trials, they delayed progression in new-onset T1D (68). Here, JAK1 is linked to type 1 diabetes mellitus.